PBMCs and Other Specimens from RCC Patients Receiving Treatment with Immunomodulatory Agents , Canada

Registration Status: Completed

Objective: We are interested in immunological changes, including altered anticancer T cell responses, in patients with kidney cancer following treatment with immunomodulatory agents. These include programmed death-1 (PD-1)-based checkpoint inhibitors and mammalian target of rapamycin (mTOR) inhibitors.

Registered Biobank Name PBMCs and Other Specimens from RCC Patients Receiving Treatment with Immunomodulatory Agents
Biobank Leader S.M. Mansour Haeryfar
Country Canada
Email for biobank inquiries Mansour.Haeryfar@schulich.uwo.ca
Principal Investigator Dr. S.M. Mansour Haeryfar
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Biospecimen Collected: